Acupuncture Therapy for COVID-Related Olfactory Loss
Study Details
Study Description
Brief Summary
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Acupuncture Therapy Group Subjects will undergo ten sessions of acupuncture therapy with a licensed acupuncturist in addition to the standard of care. |
Device: Acupuncture Therapy
Consists of two treatments per week for five weeks
Drug: Budesonide
Twice daily nasal rinses with steroid medication (budesonide)
Other: Olfactory Training
involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
|
| Active Comparator: Standard of Care Subjects will be treated with two times daily budesonide rinses and olfactory (sense of smell) training. This is considered the current standard of care in the treatment of olfactory dysfunction. |
Drug: Budesonide
Twice daily nasal rinses with steroid medication (budesonide)
Other: Olfactory Training
involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
|
Outcome Measures
Primary Outcome Measures
- Change in UPSIT scores [Baseline, post-treatment approximately 12 weeks]
Secondary Outcome Measures
- Change in patient-reported subjective olfactory loss [Baseline, post-treatment approximately 12 weeks]
Patient-reported subjective olfactory loss measured by a 10-point visual analog scale with 0 representing no sense of smell and 10 representing normal smell.
- Change in Sino-Nasal Outcome Test (SNOT-22) [Baseline, post-treatment approximately 12 weeks]
Patient-reported subjective olfactory loss measured by SNOT-22 questionnaire, rating symptoms experiences from 0 = no problem, 5 = problem as bad as it can be
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years or older.
-
Patients with post-viral olfactory dysfunction > 4 weeks.
-
History of positive COVID-19 PCR.
Exclusion Criteria:
-
Less than 18 years of age.
-
Active sinus infection.
-
New diagnosis of untreated CRS.
-
Prior diagnosis of dementia or Parkinson's disease.
-
Prior head trauma or neurosurgical procedure resulting in olfactory loss.
-
Patients who do not speak or read English.
-
Patients unable to understand and sign the study consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: Janalee Stokken, MD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 21-003531